secwatch.observer — SEC 8-K summary
======================================

Issuer:     TELA Bio, Inc. (TELA)
CIK:        0001561921
Form:       8-K
Filed at:   2023-05-11T23:59:59+00:00
Accession:  0001104659-23-059119
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

TELA Bio Q1 revenue $11.9M (+45% YoY); reaffirms FY2023 guidance $60M-$65M
--------------------------------------------------------------------------

- Revenue $11.9M, up 45% YoY; OviTex revenue +42%, OviTex PRS +52%.
- Gross margin improved to 66% from 61% due to better inventory management.
- Net loss $12.0M vs $10.9M; operating loss $11.3M vs $9.8M.
- Closed public offering netting ~$46.4M; cash $30.1M at quarter end.
- Reaffirms FY2023 revenue guidance $60M-$65M (45-57% growth).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1561921/000110465923059119/0001104659-23-059119-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1561921/000110465923059119/tm2315327d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-059119

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer